Clinical trial Recruiting at 1 site Interventional Ages 18 to 55

Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression

Official title: Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression

Run by Gulhane Training and Research Hospital · NCT07673913 · Data updated 2026-11-12

This study tests whether a four-week course of intermittent theta burst stimulation can help people with treatment-resistant depression by looking at symptoms, thinking skills, and blood biomarkers.

More Major Depression trials

Quick facts

Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment100 (estimated)
SponsorGulhane Training and Research Hospital
Government
Locations2 sites (Ankara, Ankara and 1 other locations)
StatusRecruiting
StartedSeptember 1, 2026
Main results expectedSeptember 1, 2027
Study endsSeptember 1, 2027
Registry record updatedSeptember 14, 2026
Trial IDNCT07673913 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-55 with a DSM-5-TR diagnosis of major depressive disorder who have failed at least two adequate antidepressant trials.

Probably not a fit

Individuals unable to complete the iTBS protocol or without a biological response profile may not experience meaningful benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center study enrolling 50 adults with treatment-resistant depression and 50 healthy controls. Participants with TRD receive active iTBS to the left dorsolateral prefrontal cortex over 20 sessions in four weeks, while controls provide baseline comparisons. The research will assess clinical symptoms, executive function, and peripheral inflammatory and neuroprotective biomarkers to explore mechanisms of response. The trial aims to identify potential biomarkers that correlate with treatment outcomes and to deepen understanding of how iTBS affects neurobiology in TRD. The study is investigator-initiated and conducted at Gulhane Training and Research Hospital in Ankara, Turkey.

Why it matters

Potential benefit: If successful, patients with TRD could experience improved depressive symptoms and functional outcomes from iTBS, possibly enabling more personalized treatment strategies.

How similar studies have gone: Previous neuromodulation studies suggest iTBS can alleviate depressive symptoms, but biomarker-guided prediction remains an emerging area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

Treatment-Resistant Depression Group:

Age between 18 and 55 years. Male or female participants. Diagnosis of Major Depressive Disorder according to DSM-5-TR criteria. Inadequate response to at least two antidepressant treatments administered at adequate doses and durations.

Eligible for transcranial magnetic stimulation (TMS) treatment. Able and willing to provide written informed consent. Able to complete neuropsychological assessments. Able to attend study visits and complete the treatment protocol.

Healthy Control Group:

Age between 18 and 55 years. Male or female participants. No current DSM-5-TR psychiatric disorder. Able and willing to provide written informed consent. Able to complete neuropsychological assessments.

Exclusion Criteria

Schizophrenia, bipolar disorder, organic mental disorders, or other major psychiatric disorders.

History of epilepsy, brain tumor, severe head trauma, or significant neurological disease.

Any contraindication to TMS. Presence of intracranial metal implants, cardiac pacemakers, cochlear implants, or other incompatible implanted devices.

Active infection. Autoimmune disease or chronic inflammatory disease. Electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation within the previous 5 years.

Previous intravenous or intranasal ketamine treatment. Pregnancy or breastfeeding. Active alcohol or substance use disorder. Inability to comply with study procedures. Inability to tolerate the iTBS protocol. Withdrawal of informed consent at any stage of the study.

Where it's running

  • Gulhane Training and Research Hospital
    Ankara, Turkey (Türkiye)
    Recruiting
  • Gulhane Training and Research Hospital
    Ankara, Ankara, Turkey (Türkiye)
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.